Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2026 MDS Highlights
01 July 2026 | Virtual Meeting
Post-EHA 2026 MDS Highlights
Featuring presentations & discussions on selected MDS abstracts from the 31st Congress of the European Hematology Association (EHA).
Chair: Amer Zeidan | Moderators: Yasmin Abaza & María Díez Campelo
Session1: Updates in low-risk MDS management
Luspatercept (luspa) initiated at the maximum-approved dose in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require transfusions: Primary analysis from MAXILUS
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Early versus delayed ESA in lower-risk non-transfusion-dependent MDS: Final Phase III EPO-PRETAR results on transfusion dependence and erythroid response
Sophie Park CHU Grenoble Alpes, Grenoble, France
Ofirnoflast, a first-in-class NEK7 inhibitor, induces robust transfusion independence and multilineage hematological improvement in lower-risk myelodysplastic syndrome (LR-MDS)
Varun Bafna Kolhapur Cancer Centre, Gokul Shirgaon, India
Roxadustat improves transfusion independence in LR-MDS patients with anemia and high transfusion burden and in ring sideroblast positive and negative disease: Post-hoc analysis of MATTERHORN study
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Panel discussion
Session 2: Recent progress in the management of AML and high-risk MDS
Translational insights and clinical efficacy with bexmarilimab and azacitidine in HR-MDS in the BEXMAB Phase 1/2 study
Mika Kontro University of Helsinki, Helsinki, Finland
CPX-351 versus standard of care as bridging to allo-HCT in patients with higher-risk myelodysplastic neoplasms or oligoblastic acute myeloid leukemia: Results of the randomized Phase 2 PALOMA study
Madlen Jentzsch Leipzig University Hospital, Leipzig, Germany
Safety, tolerability, and efficacy of mesutoclax (ICP-248) in combination with azacitidine in patients with myeloid malignancies
Huafeng Wang First Affiliated Hospital of Zhejiang University School of Medicine (FAHZU), China
Panel discussion
Session 3: Latest in TP53-mutated MDS
Functional TP53 phenotype score refines prognostic stratification in monoallelic TP53-mutated myelodysplastic neoplasms beyond allelic state
Alexander Streuer Heidelberg University, Mannheim, Germany
Allogeneic HSCT for TP53-aberrant myeloid neoplasms: Real-world outcomes from a Scandinavian multicentre cohort
Anders Myhre Oslo University Hospital, Oslo, Norway
Session 4: Advances in prognostics & latest RWE
VEXAS prognostic score: Personalized machine learning derived risk stratification model
Tariq Kewan Yale School of Medicine, New Haven, CT, United States
Hypomethylating agents with or without venetoclax in treatment-naïve myelodysplastic syndromes with excess blasts: Results from a large retrospective cohort
Alex Bataller The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
